Amevive Wisdom Acquired From Real-Time Evidence (A.W.A.R.E™) Program

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00371774

Enrollment

426

Registered

2006-09-04

Start date

2005-06-30

Completion date

2008-05-31

Last updated

2011-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plaque Psoriasis

Keywords

Psoriasis, Plaque Psoriasis, Amevive®, alefacept

Brief summary

Purpose: To develop a real time national clinical database to support and share best practices, 1. To generate hypotheses for future clinical research 2. To understand how AMEVIVE is used in routine clinical practice/real world setting. Each patient visit will include the following observational endpoints: 1. AMEVIVE dosing 2. Number of courses 3. Concomitant treatment 4. Response to treatment (patient and physician global assessments) 5. Status of other psoriasis-related medical conditions 6. Time to re-treatment.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

16 Years to No maximum

Healthy volunteers

Inclusion criteria

* Amevive is clinically indicated for the patient

Exclusion criteria

* Amevive is contraindicated for the patient

Design outcomes

Primary

Measure	Time frame
Understand how AMEVIVE is used in routine clinical practice/real world setting	End of study

Countries

Canada

Outcome results